CervoMed adds McKinsey veteran David Quigley to board of directors

CervoMed Inc. (NASDAQ: CRVO) appointed David Quigley to its board of directors, the clinical-stage biotechnology company announced Monday. Quigley served as a senior partner at McKinsey & Company for more than 25 years, where he led the firm's Private Capital practice and various Life Sciences practices.

The appointment comes as CervoMed prepares for U.S. Food and Drug Administration feedback on its planned Phase 3 trial design for patients with dementia with Lewy bodies, expected in the fourth quarter of 2025. The company develops treatments for age-related brain disorders.

"His strategic insight and commercial acumen are ideally suited to support CervoMed's mission as we advance neflamapimod toward transformative milestones," said Joshua Boger, chair of CervoMed's board and founder of Vertex Pharmaceuticals.

Quigley held leadership roles at McKinsey including Global Head of Private Capital, North America Head of Life Sciences, and Global Lead of Life Sciences Commercial. He has been a guest lecturer on Life Sciences at Columbia University's Mailman School of Public Health.

"David's deep industry knowledge and proven track record supporting successful pipeline and commercial development, partnering, and M&A will be invaluable as we progress our planned Phase 3 program in DLB," said John Alam, CervoMed's president and chief executive officer.

CervoMed's lead drug candidate, neflamapimod, completed a Phase 2b trial called RewinD-LB in patients with dementia with Lewy bodies. The company plans to initiate a global Phase 3 trial in the same patient population in mid-2026.

Dementia with Lewy bodies is the second most common progressive dementia after Alzheimer's disease. No approved treatments exist for the condition in the United States or European Union.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Heidi L. O'Neill resigns from Lithia Motors board
• Monster Beverage CEO Americas to resign, interim successor named